Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Topas Therapeutics GmbH. (4/24/18). "Press Release: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement". Hamburg.

Organisations Organisation Topas Therapeutics GmbH
  Organisation 2 Boehringer Ingelheim (Group)
Products Product immuno modulatory compound (IMO)
  Product 2 viral vector_o
Index term Index term Boehringer–Topas Therapeutics: immuno modulatory compounds, 201804– collab €na multi-y research + option agreem
Persons Person Jessen, Timm-Heinrich (Topas Therapeutics 201510– Managing Director before Bionamics + Scienamics + Evotec OAI)
  Person 2 Hennecke, Anne (MC Services 201211 Managing Partner before Evotec + Schwarz Pharma)
     


> Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies)

> Initial focus on next generation vector-based therapeutics

> Boehringer Ingelheim is granted option to in-license several pre-clinical development candidates produced under the collaboration


Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that it has signed a multi-year agreement with Boehringer Ingelheim to collaborate in the field of antigen-specific tolerance induction with an initial focus on virus-based delivery vectors that confer novel therapeutics to patients.

Virus-based therapeutics are emerging as a promising new approach to the treatment of cancer, with applications such as oncolytic viruses and also delivery vectors for cancer vaccines. However, as with any virus, the body may develop an unwanted immune reaction, prohibiting repeated administration of the viral therapeutic and possibly limiting its utility. In this collaboration, the Topas tolerizing nanoparticle technology will take aim at preventing this vector-neutralizing response.

Under the terms of the agreement, Topas will be responsible for the design, application and production of its proprietary tolerizing particles while Boehringer Ingelheim will contribute its antigen know-how and its pharmacology expertise to the collaboration in order to develop tolerance-generating adjuvant candidates. Boehringer Ingelheim has an option to license several pre-clinical development candidates produced under the collaboration for development and commercialization. Financial details of the agreement were not disclosed.

Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. Peptide-loaded nanoparticles mimic bloodborne antigens, selectively target liver sinusoidal endothelial cells (LSECs), and generate antigen-specific regulatory T cells that suppress unwanted immune reactions.

Timm Jessen, CEO of Topas Therapeutics, said: “We are proud to be working with Boehringer Ingelheim to generate novel product candidates using our proprietary technology. This collaboration supports the value and broad applicability of our tolerance induction approach, now comprising the increasingly significant field of novel therapeutics and their precise delivery. The high level of interest we have seen in our technology, including this key collaboration with Boehringer Ingelheim, supports the growing recognition of the importance of tolerance induction in drug development, and we believe will fuel Topas’ future commercial potential.”


About Topas Therapeutics GmbH

Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen- specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has two programs preparing to enter the clinic in 2019 including one for an orphan disease. Topas also has a research and option agreement with Eli Lilly and Company focused on immune tolerance and a co-development agreement with Evotec for a Type 1 diabetes program that is currently in pre-clinical testing. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. For additional information, please visit: www.topas-therapeutics.com.


Topas Therapeutics GmbH

Dr. Timm-H. Jessen
CEO / Managing Director
Falkenried 88
20251 Hamburg

Email: jessen@topas-therapeutics.com
Web: www.topas-therapeutics.com


Media Relations Europe

MC Services AG
Anne Hennecke
Phone: +49 211 529252-22
Email: anne.hennecke@mc-services.eu


Media Relations U.S.

Laurie Doyle
Phone: +1 339 8320752
Email: laurie.doyle@mc-services.eu
Web: www.mc-services.eu

   
Record changed: 2018-04-25

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Topas Therapeutics GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top